PTPRR

Across TCGA pan-cancer cohorts, PTPRR Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PTPRR data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PTPRR Mutation is associated with better overall survival. In most high-consensus cancer types, elevated PTPRR expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

UCEC, PRAD, and LUAD are the cancer types where PTPRR Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	II,III,IV	0.937	0.454	.013	26	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	II,III,IV	0.090	0.677	<.001	6	view →
LUSC	OS	Median	All	0.685	0.395	.037	3	view →
SKCM	DFS	Median	All	0.339	0.648	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PTPRR–UCEC (OS)

Open the UCEC breakdown →